Attendee search 

Fosunpharma is a leading healthcare group in China. It has built a strong root domestically and developed a global operation strategy. With pharmaceutical manufacturing and R&D being core business segment, together with strong presences in medical devices and diagnostics, healthcare services, pharmaceutical distribution and retail.

Keytone is a venture firm with AUM over $400m.

Link Health is a leading Chinese pharmaceutical company based in Southern China, focusing on the development of innovative drugs for the unmet medical needs.
Link Health has created a highly professional team with diverse expertise in drug development, medical affairs and regulatory affairs. Leveraging deep understanding of China market, favourable regulatory environment and strong network with global biopharmaceutical companies, Link Health is well positioned to bring innovative drugs to the market efficiently.
The company has established a fully owned subsidiary in Amsterdam, the Netherlands. The Dutch office focuses on collaborations with global pharma/biotech partners and research institutes.

We are a clinical stage biopharmaceutical company advancing a robust pipeline of drug candidates to address a spectrum of large, unmet medical needs. We are focused on harnessing powerful, untapped biology underlying major diseases to develop transformative therapeutics for patients.

leadermed Group是一家将美国正在临床阶段创新药license in China以及亚洲部分国家的公司，致力于将国外最新研究成果以最快速度让China乃至亚洲其他国家患者使用上国际最安全有效创新药，将来也将自主研发我们China人自己的创新药，为世界上所有患者服务！

MedWorld Advisors is an international M&A Services Firm. We represent medical technology companies from the US, EU and Israel that want to enter the China market. We facilitate licensing, commercialization and acquisition deals between our clients and larger companies / investors in China. We are based in Boston in the U.S. We also have an operation in Hong Kong to help facilitate deals, as helpful.

UK Pharmaceutical

MAVIE Technologies is an investment banking boutique in Chinese-Western healthcare transactions providing commercially-focused, end to end advice to maximize deal certainty and increase the intended value of transactions. Our team combines deal structuring sophistication and experience - whether it is private placement, secondary shares sale, joint-venture, licensing or M&A - with deep Chinese healthcare insights, strategic thinking and proprietary access. We add unique value in visualizing, negotiating and closing the deal.

Wanbang Biopharmaceuticals (Wanbang Biopharma) is a core member of Shanghai Fosun PHARMACEUNCAL (group) Co., Ltd.(Fosun Pharma”, Stock code: 600196-SH,02196-HK).